Life sciences company Revvity (NYSE:RVTY) in Q2 CY2025, with sales up 4.1% year on year to $720.3 million. The company expects the full year’s revenue to be around $2.86 billion, close to analysts’ ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert ...

Revvity, Inc. RVTY recently introduced Signals Xynthetica, a next-generation AI-augmented design platform aimed at transforming molecular and materials discovery across scientific industries.

When PerkinElmer’s diagnostics and life sciences businesses separated from its food safety, environmental testing and industrial quality assurance segments and rebranded as Revvity earlier this year, ...

Life sciences company Revvity (NYSE:RVTY) announced in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0 ...

Revvity (NYSE:RVTY) has had a great run on the share market with its stock up by a significant 10% over the last three months. But the company's key financial indicators appear to be differing across ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a new license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for the technology underlying its Pin-point™ base editing ...

In the last three months, 7 analysts have published ratings on Revvity (NYSE:RVTY), offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their ...

Waltham-based biomanufacturing company Revvity is closing its Boston facility and laying off dozens of employees as a result. Revvity filed a public Worker Adjustment and Retraining Act Notification ...

Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company’s website. Replays of the ...